Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cameron J Turtle

Showing results (51-60 of 129) with videos related to

Pageof 13
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 17, 2019
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T CellsAna Cordeiro, Evandro D Bezerra, Alexandre V Hirayama, et al.
Blood|February 25, 2016
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapyRebecca Gardner, David Wu, Sindhu Cherian, et al.
Blood|March 23, 2011
HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivoAude G Chapuis, Corey Casper, Steve Kuntz, et al.
Hemasphere|August 8, 2024
PD-L1<sup>+</sup> macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacyAlexandre V Hirayama, Jocelyn H Wright, Kimberly S Smythe, et al.
Journal of Immunological Methods|March 1, 2003
Single step enrichment of blood dendritic cells by positive immunoselectionJ Alejandro López, Gilles Bioley, Cameron J Turtle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2017
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of IbrutinibCameron J Turtle, Kevin A Hay, Laïla-Aïcha Hanafi, et al.
JCO Clinical Cancer Informatics|January 30, 2026
Novel R Shiny Tool for Survival Analysis With Time-Varying Covariate in Oncology Studies: Overcoming Biases and Enhancing CollaborationYimei Li, Yang Qiao, Fei Gao, et al.
Blood|May 28, 2020
Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?Matthew J Frigault, Sarah Nikiforow, Michael K Mansour, et al.
The Lancet. Respiratory Medicine|January 18, 2021
Assessing the importance of interleukin-6 in COVID-19 - Authors' replyDaniel E Leisman, Lukas Ronner, Rachel Pinotti, et al.
JCO Clinical Cancer Informatics|April 20, 2026
Erratum: Novel R Shiny Tool for Survival Analysis With Time-Varying Covariate in Oncology Studies: Overcoming Biases and Enhancing CollaborationYimei Li, Yang Qiao, Fei Gao, et al.
Pageof 13

Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 17, 2019
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T CellsAna Cordeiro, Evandro D Bezerra, Alexandre V Hirayama, et al.
Blood|February 25, 2016
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapyRebecca Gardner, David Wu, Sindhu Cherian, et al.
Blood|March 23, 2011
HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivoAude G Chapuis, Corey Casper, Steve Kuntz, et al.
Hemasphere|August 8, 2024
PD-L1<sup>+</sup> macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacyAlexandre V Hirayama, Jocelyn H Wright, Kimberly S Smythe, et al.
Journal of Immunological Methods|March 1, 2003
Single step enrichment of blood dendritic cells by positive immunoselectionJ Alejandro López, Gilles Bioley, Cameron J Turtle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2017
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of IbrutinibCameron J Turtle, Kevin A Hay, Laïla-Aïcha Hanafi, et al.
JCO Clinical Cancer Informatics|January 30, 2026
Novel R Shiny Tool for Survival Analysis With Time-Varying Covariate in Oncology Studies: Overcoming Biases and Enhancing CollaborationYimei Li, Yang Qiao, Fei Gao, et al.
Blood|May 28, 2020
Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?Matthew J Frigault, Sarah Nikiforow, Michael K Mansour, et al.
The Lancet. Respiratory Medicine|January 18, 2021
Assessing the importance of interleukin-6 in COVID-19 - Authors' replyDaniel E Leisman, Lukas Ronner, Rachel Pinotti, et al.
JCO Clinical Cancer Informatics|April 20, 2026
Erratum: Novel R Shiny Tool for Survival Analysis With Time-Varying Covariate in Oncology Studies: Overcoming Biases and Enhancing CollaborationYimei Li, Yang Qiao, Fei Gao, et al.
Pageof 13